
News|Articles|November 2, 2026
FDA news in pediatrics: October 2026
Author(s)Contemporary Pediatrics Staff
Fact checked by: Morgan Ebert, Executive Editor
A recap of the top FDA approvals, regulatory decisions, and pipeline updates affecting pediatric care during October 2026.
Advertisement
Advertisement
October's FDA pediatric news clustered around label expansions that extend already-approved adult or older-adolescent therapies down to younger age groups and formulations that ease dosing, alongside a Breakthrough Therapy designation for a rare dermatologic condition and continued movement on a long-delayed epinephrine alternative. Together, the month's items illustrate how the agency increasingly leans on extrapolated adult data and dosing/formulation studies, rather than dedicated pediatric efficacy trials, to broaden pediatric access.
Related to this article

The FDA approved once-weekly somapacitan-beco for growth failure in Turner syndrome in children aged 2.5+ years, based on phase 3 REAL8 data.

In a phase 2 trial, tofacitinib met its safety end point and lowered interferon and cytokine scores in adolescents and adults with Down syndrome.

The FDA approved oral venglustat for neurological symptoms of type 3 Gaucher disease in patients ≥15 kg, based on phase 3 LEAP2MONO data.

Laura Tochen, MD, of Children's National Hospital, discusses how the first disease-modifying therapy for Alexander disease could change care and diagnosis.

In SURMOUNT-ADOLESCENTS, tirzepatide cut BMI 18.5% at 72 weeks vs a 0.5% rise with placebo in adolescents with obesity.

Caregivers reported itch, symptom, and QOL gains with roflumilast cream 0.05% in infants with AD; an FDA decision is due February 2027.

Novo Nordisk filed etavopivat for SCD in patients aged 12+, backed by phase 3 HIBISCUS data showing a 27% drop in vaso-occlusive crises vs placebo.
Advertisement
Advertisement

